← Back to all trials
Recruiting
NCT06091319
Florbetaben for Imaging of Vascular Amyloid
Conditions: Acute Coronary Syndrome, Stroke, Transient Ischemic Attack, Atherosclerosis of Artery
Sex: All
Ages: 18 Years – N/A
Healthy volunteers: Yes
Enrollment: 30
Sponsor: Ottawa Heart Institute Research Corporation
Location: University of Ottawa Heart Institute Ottawa Ontario
Summary
The Primary Objective is to determine if a new nuclear tracer (named 18F-Florbetaben) used with nuclear imaging (PET imaging) can detect inflamed plaque in patients with recent ACS or stroke/TIA.
Eligibility Criteria
Inclusion Criteria:
1. suffered a recent cardiovascular event (30-120 days post ACS (i.e. STEMI or NSTEMI) or TIA/stroke with ipsilateral large vessel atherosclerotic disease confirmed on US, CT or MRI;
2. stable symptoms and hemodynamics;
3. age \>/= 18 years;
4. given informed consent.
Exclusion Criteria:
1. a recent CV event likely to have been embolic in the opinion of the neurologist or cardiologist;
2. severe LV dysfunction (EF\
Source: ClinicalTrials.gov (NCT06091319). StuddyBuddy aggregates publicly available trial information.
